Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 71

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 71
---

statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, that relate to future events or our future financial performance and involve known and unknown risks, uncertainties
and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future
results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Such forward-looking
statements concern our anticipated results and progress of our operations in future periods, planned exploration and, if warranted, development
of our properties, plans related to our business and other matters that may occur in the future. These statements relate to analyses and
other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.
All statements contained herein that are not clearly historical in nature are forward-looking, and the words “anticipate,”
“believe,” “expect,” “estimate,” “may,” “will,” “could,” “leading,”
“intend,” “contemplate,” “shall” and similar expressions are generally intended to identify forward-looking
statements. Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could
cause actual events or results to differ from those expressed or implied by the forward-looking statements. The sections in this prospectus
entitled “Risk Factors,” “Business” and “Management’s Discussion and Analysis of Financial Condition
and Results of Operations,” as well as other sections in this prospectus, discuss some of the factors that could contribute to these
differences. Forward-looking statements in this prospectus include, but are not limited to, statements with respect to:

| - | our limited operating history and experience in developing and manufacturing drugs; |

| - | none of our products are approved for commercial sale; |

| - | our substantial capital needs; |

| - | product development risks; |

| - | our lack of sales and marketing personnel; |

| - | regulatory, competitive and contractual risks; |

| - | no assurance that our product candidates will obtain regulatory approval or that the results of clinical 
 studies will be favorable;                                                                               |

| - | risks related to our intellectual property rights; |

| - | the volatility of the market price and trading volume in our Common Stock; |

| - | the risk that our Common Stock will be delisted from Nasdaq; |

| -